The in vitro experimental evidence suggested that CAF-derived FGF7 can promote the cell growth and cell invasion of ccRCC tumor cells, which are mitigated by a specific inhibitor of the PI-3K/AKT signaling pathway. This evidence concerns the gene FGF7 and nonpapillary renal cell carcinoma.